Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival BioSpaceIn a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacyNext: 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
